I'm an investor and a Chartered Business Valuator (CBV). I have been investing since I was a teenager. I love my work. I manage a private investment company and I specialize in business valuation.
I'm a huge skeptic by nature. If you had to put me in an investment category, I would fall under "contrarian/value" investor. It's not an investment style that I picked but one that reflects my personality.
Regarding my articles, I think to present my ideas present in a neutral light, without any hype or promotion, which is a rare thing these days.
Please note that any articles or comments on Seeking Alpha are not linked to my work, and the opinions or content mentioned are mine personally.
Elephant Analytics has an Bachelor of Business Administration degree with a concentration in marketing and finance, and 13 years of experience as an analyst. Elephant Analytics originally focused on marketing and sales analysis due to geographical and lifestyle considerations, but rekindled his interest in finance and investing several years ago and became a contributor to Seeking Alpha in 2013. He has a particular interest in attempting to understand distressed companies and distressed industries.
Elephant Analytics has unique skills in the areas of numerical analysis and applied mathematics. Elephant Analytics achieved a top 50 score on the Bloomberg Aptitude Test (out of nearly 200,000 test takers) which measures financial aptitude. Elephant Analytics also has achieved a score (153) in the 99.98th percentile on the WAIS-III IQ test and has also been involved in multiple teams that have won awards during business and strategy competitions involving numerical analysis. In one such competition, he captained his team to become North American champions, ahead of MBA and undergraduate teams from universities such as Harvard, Yale and Northwestern.
Legal Disclaimer: Elephant Analytics' reports, premium research service and other writings are personal opinions only and should not be considered as investment advice. Only registered investment advisors can provide personalized investment advice. While Elephant Analytics attempts to provide reports that include accurate facts, investors should do their own diligence and fact checking prior to making their own decisions.
Richard Moheban (aka Retired Aviator) earned a BBA in Finance, Investment & Banking from a national top ten (public) business school—the University of Wisconsin at Madison. He then went on to earn a BFA (with Honors) in 1992. After that, however, his one year of working in the corporate world was enough for him to realize that it was not his cup of tea. He decided he needed more freedom and daily variety than any Finance position could offer, so he went to work for himself.
Determined to somehow achieve financial independence without the grind, he worked as many as four part-time jobs concurrently to obtain seed cash for investing. He devoted much of his non-working time to studying investments and "real world" Economics (as opposed to the academic variety), refining several workable theories along the way. For years he plowed every spare nickel into investing. Using only his relatively modest sources of income as an investing base, over time he was able to multiply his savings and thus achieve his dream of retiring by his mid-forties in 2009. Today he enjoys pursuing a variety of recreational interests, researching, writing, and has several ideas in the works for new books. He has one book published to date.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
A long time Senior Corporate Financial Analyst for DLLR, RAD and others.
Projects included.... budgets, 5 year forecasts, same store sales analysis, loan proposals, joint venture proposals and BOD presentations, etc.
Currently an active Investor.
I retired as CEO of an Automotive Parts supplier, and manage an investment portfolio for myself and family. I have a BA in History from Royal Military College of Canada and an MBA from the University of Western Ontario. My first career was as a fighter pilot in the RCAF, and, following my MBA I joined McKinsey & Company, Inc. leaving them for Canadian GE. I left CGE as a Vice President in 1984 and founded The Enfield Corporation Limited ("Enfield") which grew from 243 employees in 1984 to over 10,000 in 1989 when Enfield was taken over and I was replaced as CEO. In 1989, I acquired control of Algonquin Mercantile Corporation, renamed Automodular Corporation in the late 1990's when I turned it to focus exclusively on automotive parts sub-assembly. Along the way, Algonquin turned a few ageing drug stores into Pharmx Rexall Drug Stores Ltd., sold to Katz group in 1997 and today a major Canadian drug store chain.
I have been a private investor since 1971 both directly and through a private company controlled by myself and members of my family.
Investment professional with over ten years of Wall Street experience. I began my career in investment banking at Merrill Lynch. Following my time at Merrill, I worked for approximately seven years in private equity. Currently, I manage money for both qualified and non-qualified clients. I would classify myself as a long/short investor with a value-based approach.
D.B. Research is a research firm focused on Chinese due diligence. Nearly all of our bilingual team is located on ground in China which gives us a significant advantage in determining the legitimacy of a given company. Presently we expect to be publishing mainly short ideas as our specialty is identifying and investigating fraudulent companies.
Independent writer/trader/investor whose primary interests are in the stem cell and biotech arena. Secondary interest is in oil/energy speculation. There’s an option to follow me at the top of any article I write. Click it and you’ll also see an option to get real time alerts. Read on desktop for full functionality of this site.
OTHER PLACES TO FOLLOW ME:
I’M NOT A FINANCIAL ADVISOR & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;) Investment Philosophy: Understand why you are getting in and cut your loss immediately if PPS goes down while behaving differently than you expected. Don't ride it down! I never go all in on any one stock and take the basis off the table when possible. Another thought is to never ride through a binary event such as a trial ending without a hedge of some kind. I never put in more than I can afford to lose if the trade goes wrong. My positions, long or short can change dramatically as new information comes to my attention. And, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment. All stocks are risky, especially, biotech.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)
Retired mechanical engineering designer. Specialized in clean air, water & process gases for semiconductor industry. Now I just piddle around designing PCB and mechanical contraptions for a local electrical inverter manufacturer and following the markets.
Mike Holt is a Senior VP, Wealth Management Strategist with The MDE Group, an innovative Wealth Management Firm located in Morristown, NJ that manages over $1 billion for corporate executives and other high net worth individuals located across the US. Mike's diverse background includes auditing financial services firms in NY for a Big 4 CPA firm, a 3-year foreign assignment to Saudi Arabia during which he also travelled extensively, primarily in Europe, Africa, the Middle East, and Asia, and the provision of sophisticated income and estate tax services to partners, directors, and executives at ARAMCO, KKR, Citibank, Lloyds, Lehman Brothers, McKinsey & Co., and Pfizer among others.
He is also a CFP and a PFS, and since 1994 he has been helping clients of The MDE Group to accumulate wealth, and then to preserve that wealth against the backdrop of an increasingly uncertain economic and market environment. Mike's dedication to his clients has driven him to draw upon his broad experience and intense curiosity about the world to investigate global macro risks that have become increasingly relevant to both the successful management of their portfolios and, more importantly, their overall financial well being and that of their families.
Mike earned a Bachelor of Science in Business Administration from Cal State, Long Beach and participated in the MS Taxation program at Pace University in New York.
Please note that the views I express in my posts and comments do not always reflect the views of The MDE Group.
I have over 20 years of investment and financial management experience, and have actively managed my own investment portfolio for 15 years.
I have held management positions with multiple large companies, including Fortune 500.
I'm a long-term investor. My current portfolio comprises of small cap growth, dividend paying stocks, and high yield ETFs. Largest stock holdings: TSLA (since IPO), KNDI.
I'm fascinating with green technologies, and special situation. Currently electric car companies and China's embrace of NEV are on the top of my list.
Follow me on StockTwits (mnguyen_saa). I frequently post breaking news from China, charts, facts etc. mostly for KNDI, and some TSLA.
Forty year career in finance and executive management beginning on Coopers & Lybrand audit staff (CPA) culminating with twenty-six years as CEO of publicly-held companies. Prior to that and after leaving C&L served in CFO and COO capacities, all in publicly-held companies. Was an EDGAR Pilot Program filer in 1984, one of eighteen if my memory is correct.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
Anita Dushyanth is a Biotechnology Technology and Medical Devices Analyst with Zacks Investment Research.
She has worked as a researcher in the field of Bioengineering at the University of California, Los Angeles (UCLA) for over 10 years. Her expertise includes research that delves into the biomechanics of the human body, degenerative disease progression, quantitative image analysis and optimization, and design and development of medical compliant devices. She has published and presented several research articles and has also been a peer reviewer and an editor for a number of prestigious journals in the field of biomedical engineering. Prior to that, Anita worked as a researcher at the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF).
Anita holds a PhD degree in Bioengineering from UCLA, M.S. in Biomedical Engineering from Wright State University, Dayton, OH and B.S. in Instrumentation Engineering from the University of Madras, India.
Trained at Goldman Sachs as an analyst and then did fixed-income and multi-strategy arbitrage for hedge fund Mariner Investment Group before starting his own hedge fund. Specialize in special situations and market neutral quantitative strategies.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
We look for undervalued small and micro-cap equities to provide the maximum ROI for shareholders. We do so through a combination of many factors, but most importantly, we look for companies that are currently generating revenue, have significant potential for growth, and a minimal risk profile.
In 1981 Allen founded Allen and Caron, which now has offices in Irvine, California, and New York City, with affiliates in London and Milan. He spent the 1970s in various areas of media and communications. Initially he was an editor and later a marketing manager for scholarly and educational book publishers; he then moved on to serve in the cutting-edge public affairs department at Atlantic Richfield Company in the mid-1970s. When he left Atlantic Richfield, he became vice president and general manager of the southern California region of Bozell & Jacobs Public Relations.
Allen has served on the boards of several small companies, including Westergaard.com, the publishing enterprise of the late John Westergaard. He is the co-author of a college text on system life cycles and books on business communications and continuing education. He has written a book on sandcastles, and has written on a variety of topics for numerous leading magazines and newspapers, and has been active in several charities. He is currently working on a family memoir and a novel.
Allen has also been a contributing author for the "Inside the Minds" series of C-Level Business Intelligence™ books published by Aspatore Books, a Thomson Reuters business. His contributions include a chapter in Public Relations Leadership Strategies titled Investor Relations: Creating a Dialogue with the Investor and a chapter in Public Relations Best Practices 2008-2009 titled Cross-Border Companies: A Fast-Increasing Trend in Investor Relations.
I hold MSc. in Electrical Engineering, speak four languages (English, French, Greek, German) and have lived in the U.S. for many years. I am also a freelance writer with one of the highest Followers per Article (F/A) rates in Seeking Alpha. My F/A rate in Seeking Alpha is above 30.
After creating "Nathan's Bulletin" (a subscription-based investment guide for investors who can't afford a financial advisor), I launched a subscription-based Premium Service in Seeking Alpha entitled "A Fundamental Investor's Stock Club" which includes an unparalleled, actively-managed and high-return Portfolio of unknown and/or underfollowed stocks. Regularly updated and detailed lists in my Premium Posts PROVE these high returns. For reference, when I was managing money in the early 2000s, the annual ROI of my Portfolio consistently exceeded 50%. My Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends.
When it comes now to my publicly-available picks and my free Seeking Alpha articles, I have a success rate of over 80%, an average return per recommendation of over 30% and a 5-star rating according to TipRanks.com, which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks 5,000 financial bloggers and 9,000 financial experts.
After almost 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), I have formulated a deep understanding of valuation analysis and my investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, I have created a unique proprietary database with thousands of publicly-traded companies per sector, which helps me spot the bargains and the bubbles before many investors find them.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
I specialize in Biotech companies. After following the sector for many years, it's my belief that a logical analysis of publicly disclosed information on a Biotech company often includes sufficient data to draw the parallels necessary to invest intelligently.
I spent many years working in various analytic jobs and trading on Wall Street. For nine of those years, I traded junk bonds for a large bank. I have an MBA from the University of Chicago, with a concentration in accounting and finance. Currently I co-manage a precious metals and mining stock investment fund in Denver. My goal is to help people understand and analyze what is really going on in our financial system and economy.
Dr. Buiel has 20 years of experience developing lithium-ion batteries, super capacitors, asymmetric lead-carbon supercapacitors, carbon-based materials for various electrochemical applications, and advanced lead acid batteries for a variety of clean technology applications. Dr. Buiel received his Ph. D. in Physics from Dalhousie University where he worked to develop low cost carbon electrode materials for lithium ion batteries. Dr. Buiel has served as the Energy Storage Group Leader for MeadWestvaco and as the Vice President and Chief Technical Officer of Axion Power International, Inc. During his time at Axion, he worked to develop advanced lead acid and hybrid lead/carbon supercapacitors for a variety of applications including hybrid vehicles, renewable energy installations, military, truck auxiliary power units, and various other clean technology applications. After leaving Axion, Dr. Buiel has started a consulting company called Coulometrics that provides manufacturing and product development R&D services for a variety of companies including a major supercapacitor company and a number of start-ups including a company focused on developing battery technologies beyond lithium-ion batteries.